Skip to main content
Journal cover image

Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes.

Publication ,  Journal Article
Alhinai, A; Patel, K; Fonseca, VA; Sebastiani, G
Published in: J Diabetes Complications
September 2021

Liver disease has emerged as a significant cause of death in people with type 2 diabetes (T2D). Due to a common underlying pathogenic mechanism, namely insulin resistance, T2D represents the main risk factor for nonalcoholic fatty liver disease (NAFLD), characterized by a buildup of fat in the liver. Globally, NAFLD is the most common liver disease, affecting a quarter of the general adult population. The development of nonalcoholic steatohepatitis (NASH) signifies an increased risk of liver fibrosis progression that can result in cirrhosis, hepatocellular carcinoma (HCC), and death. Liver fibrosis progression and development of cirrhosis is mostly asymptomatic until complications from decompensated end-stage liver disease arise. Traditionally, liver biopsy is used to diagnose NASH and stage fibrosis, however, it is invasive and costly. Non-invasive diagnostic alternatives include serum biomarkers and imaging techniques. Early identification of advanced liver fibrosis is pivotal to prompt initiation of targeted surveillance, including screening for HCC, as well as providing options for current and investigational therapeutic interventions to reduce fibrosis progression. This review gives an update on non-invasive diagnostic tools for NAFLD and liver fibrosis in the specific context of T2D, providing clinicians a pragmatic diagnostic approach to this frequent comorbidity in diabetes medicine.

Duke Scholars

Published In

J Diabetes Complications

DOI

EISSN

1873-460X

Publication Date

September 2021

Volume

35

Issue

9

Start / End Page

107978

Location

United States

Related Subject Headings

  • Non-alcoholic Fatty Liver Disease
  • Liver Neoplasms
  • Liver Cirrhosis
  • Liver
  • Humans
  • Endocrinology & Metabolism
  • Diabetes Mellitus, Type 2
  • Carcinoma, Hepatocellular
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Alhinai, A., Patel, K., Fonseca, V. A., & Sebastiani, G. (2021). Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes. J Diabetes Complications, 35(9), 107978. https://doi.org/10.1016/j.jdiacomp.2021.107978
Alhinai, Alshaima, Keyur Patel, Vivian A. Fonseca, and Giada Sebastiani. “Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes.J Diabetes Complications 35, no. 9 (September 2021): 107978. https://doi.org/10.1016/j.jdiacomp.2021.107978.
Alhinai A, Patel K, Fonseca VA, Sebastiani G. Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes. J Diabetes Complications. 2021 Sep;35(9):107978.
Alhinai, Alshaima, et al. “Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes.J Diabetes Complications, vol. 35, no. 9, Sept. 2021, p. 107978. Pubmed, doi:10.1016/j.jdiacomp.2021.107978.
Alhinai A, Patel K, Fonseca VA, Sebastiani G. Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes. J Diabetes Complications. 2021 Sep;35(9):107978.
Journal cover image

Published In

J Diabetes Complications

DOI

EISSN

1873-460X

Publication Date

September 2021

Volume

35

Issue

9

Start / End Page

107978

Location

United States

Related Subject Headings

  • Non-alcoholic Fatty Liver Disease
  • Liver Neoplasms
  • Liver Cirrhosis
  • Liver
  • Humans
  • Endocrinology & Metabolism
  • Diabetes Mellitus, Type 2
  • Carcinoma, Hepatocellular
  • 3202 Clinical sciences
  • 1103 Clinical Sciences